Apo A-I Containing Particles and Atherosclerosis
Epidemiological and clinical studies showing an association between decreased concentrations of high-density-lipoprotein (HDL) cholesterol and increased risk of premature coronary artery disease (CAD)1,2 have generated interest in the mechanism through which HDL prevents atherosclerosis. The HDL have been historically defined as lipoproteins with densities between 1.063 and 1.20 g/ml3. Human HDL consists of a collection of particles differing in size, density and apolipoprotein content4. Over the years, ultracentrifugation and, subsequently, polyanion precipitation and gradient gel electrophoresis have been used to fractionate HDL into subclasses5. Recognition of the importance of the apolipoproteins (apo) not only in the formation and structural stability of lipoproteins but also in their metabolism has led to the separation of HDL into further subpopulations according to their apolipoprotein composition rather than their physicochemical properties.
KeywordsCholesterol Electrophoresis Triglyceride Simvastatin Lecithin
Unable to display preview. Download preview PDF.
- 4.P. Alaupovic, The physicochemical and immunological heterogeneity of human plasma high density lipoproteins, in: “Clinical and Metabolic Aspects of High-Density Lipoproteins”, N.E. Miller, G.J. Miller, eds., Elsevier Science Publishers B.V., Amsterdam (1985).Google Scholar
- 5.J.C. Fruchart, S. Marcovina, and P. Puchois, Laboratory measurements of plasma lipids and lipoproteins, in: “Human Plasma Lipoprotein”, J.C. Fruchart, J. Shepherd, eds., Walter de Gruyter, Berlin (1989).Google Scholar
- 8.P. Alaupovic, E.D. Bekaert, and E. Koren, Isolation, characterization and quantitation of subclasses of plasma lipoproteins defined by their apolipoprotein composition, Atherosclerosis Rev. 20:179 (1990).Google Scholar
- 11.H.B. Brewer, D. Rader, S. Fojo, and J.M. Hoeg, Frontiers in the analysis of HDL structure, function, and metabolism, in: “Disorders of HDL”, L.A. Carlson, ed., Smith-Gordon and Company Ltd, London (1990).Google Scholar
- 12.D. Rader, J.R. Schaefer, M.R. Kindt, L.A. Zecht, J.C. Fruchart, and H.B. Brewer, Differential in vivo metabolism of HDL subclasses LpA-I and LpAI:A-II in man, Clin. Res. 38:204A (1990).Google Scholar
- 18.S. Oikawa, A.J. Mendez, M.C. Cheung, J.F. Oram, and E.L. Bierman, Effect of apo A-I and apo A-I:A-II HDL particles in intracellular cholesterol efflux, Circulation (abstract) 84(suppl II):2711 (1991).Google Scholar
- 19.W.J. Johnson, E.P.C. Kilsdonk, A. Van Tol, M.C. Phillips, and G.H. Rothblat, Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LpA-I and LpA-I:A-II, J. Lipid Res. 32:1992 (1991).Google Scholar
- 27.F. Cambien, H.J. Parra, D. Arveiler, J.P. Cambou, A. Evans, A. Bingham, Lipoprotein particles in patients with myocardial infarction and controls, Circulation 82(Supp1 III):348 (1990).Google Scholar
- 34.J.M. Bard, H.J. Parra, R. Camare, G. Luc, O. Ziegler, C. Dachet, E. Bruckert, P. Douste-Blazy, P. Drouin, B. Jacotot, J.L. De Gennes, U. Keller, and J.C. Fruchart, A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition, Metabolism 4:498 (1992).CrossRefGoogle Scholar
- 36.J.C. Fruchart, C. De Geitère, B. Delfly, G.R. Castro - Unpublished results.Google Scholar